Transcode Therapeutics, Inc. (RNAZ) intrinsic value & 10-year financials
Transcode Therapeutics, Inc. (RNAZ) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.70
- Market cap
- $1.2M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 392.0%
- Free cash flow (FY2025)
- -$19.5M
RNAZ 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$34.7M | -$52.59 | -$19.5M | — | -672.9% |
| FY2024 | — | -$16.8M | -$23.57 | -$13.4M | — | 1438.8% |
| FY2023 | — | -$18.5M | -$25.90 | -$18.1M | — | 1784.0% |
| FY2022 | — | -$17.6M | -$0.34 | -$15.9M | — | -157.9% |
| FY2021 | — | -$6.8M | -$0.20 | -$5.5M | — | -72.4% |
| FY2020 | — | -$2.3M | -$0.13 | — | — | 32.2% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Transcode Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Transcode Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -2.7% ROIC.
Transcode Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Transcode Therapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.